285 related articles for article (PubMed ID: 16388503)
1. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII.
Barrett JM; Rovedo MA; Tajuddin AM; Jilling T; Macoska JA; MacDonald J; Mangold KA; Kaul KL
Prostate; 2006 May; 66(6):632-50. PubMed ID: 16388503
[TBL] [Abstract][Full Text] [Related]
2. Bi-directional interactions of prostate cancer cells and bone marrow endothelial cells in three-dimensional culture.
Barrett JM; Mangold KA; Jilling T; Kaul KL
Prostate; 2005 Jun; 64(1):75-82. PubMed ID: 15651029
[TBL] [Abstract][Full Text] [Related]
3. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
4. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway.
Jiang J; Sugimoto Y; Liu S; Chang HL; Park KY; Kulp SK; Lin YC
Anticancer Res; 2004; 24(1):91-100. PubMed ID: 15015581
[TBL] [Abstract][Full Text] [Related]
6. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite unstable colorectal cancer cell lines with truncating TGFbetaRII mutations remain sensitive to endogenous TGFbeta.
Baker K; Raut P; Jass JR
J Pathol; 2007 Nov; 213(3):257-65. PubMed ID: 17893910
[TBL] [Abstract][Full Text] [Related]
8. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.
Pannu J; Gore-Hyer E; Yamanaka M; Smith EA; Rubinchik S; Dong JY; Jablonska S; Blaszczyk M; Trojanowska M
Arthritis Rheum; 2004 May; 50(5):1566-77. PubMed ID: 15146427
[TBL] [Abstract][Full Text] [Related]
9. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J
Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
[TBL] [Abstract][Full Text] [Related]
11. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
Chinni SR; Sivalogan S; Dong Z; Filho JC; Deng X; Bonfil RD; Cher ML
Prostate; 2006 Jan; 66(1):32-48. PubMed ID: 16114056
[TBL] [Abstract][Full Text] [Related]
12. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
14. Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells.
Rossi MR; Ionov Y; Bakin AV; Cowell JK
Cancer Genet Cytogenet; 2005 Dec; 163(2):123-9. PubMed ID: 16337854
[TBL] [Abstract][Full Text] [Related]
15. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3).
Chen A; Davis BH; Sitrin MD; Brasitus TA; Bissonnette M
Am J Physiol Gastrointest Liver Physiol; 2002 Oct; 283(4):G864-74. PubMed ID: 12223346
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
18. Stromal factors involved in prostate carcinoma metastasis to bone.
Cooper CR; Chay CH; Gendernalik JD; Lee HL; Bhatia J; Taichman RS; McCauley LK; Keller ET; Pienta KJ
Cancer; 2003 Feb; 97(3 Suppl):739-47. PubMed ID: 12548571
[TBL] [Abstract][Full Text] [Related]
19. Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro.
Cooper CR; McLean L; Walsh M; Taylor J; Hayasaka S; Bhatia J; Pienta KJ
Clin Cancer Res; 2000 Dec; 6(12):4839-47. PubMed ID: 11156243
[TBL] [Abstract][Full Text] [Related]
20. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
